Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.60 |
| ▸ | NOS1 | P29475 | 4/20 | 0.60 |
| ▸ | NOS2 | P35228 | 3/20 | 0.60 |
| ▸ | LTA4H | P09960 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080135 | 0.82 | LTA4H (0.56) | LTA4HHRH3PTGS1PTGS2ACHE | |
| SCHEMBL420575 | 0.80 | NOS3 (0.56) | NOS3NOS1NOS2LTA4HMAP4K4 | |
| SCHEMBL220877 | 0.80 | NOS3 (0.61) | NOS3NOS1NOS2LTA4HHRH3 | |
| SCHEMBL22838451 | 0.79 | LTA4H (0.56) | LTA4HHRH3PTGS1PTGS2MAP4K4 | |
| SCHEMBL221746 | 0.79 | NOS3 (0.60) | NOS3NOS1NOS2MAP4K4 | |
| SCHEMBL221914 | 0.79 | NOS3 (0.63) | NOS3NOS1NOS2LTA4H | |
| SCHEMBL6582950 | 0.78 | NOS3 (0.62) | NOS3NOS1NOS2LTA4HADORA2A | |
| SCHEMBL218605 | 0.78 | NOS3 (0.59) | NOS3NOS1NOS2LTA4HHRH3 | |
| SCHEMBL220392 | 0.78 | NOS3 (0.59) | NOS3NOS1NOS2LTA4HHRH3 | |
| SCHEMBL221361 | 0.78 | NOS3 (0.62) | NOS3NOS1NOS2LTA4HMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS3 2/4885NOS1 1/4885NOS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.